

1 **How improvements to drug effectiveness impact mass drug**
2 **administration for control and elimination of schistosomiasis**

3

4 John R. Ellis^{1*}, Nyamai Mutono^{2,3}, Andreia Vasconcelos^{4,5}, SM Thumbi^{2,3,6}, T. Déirdre Hollingsworth⁴,
5 Roy M. Anderson¹

6 ¹Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, White
7 City Campus, Imperial College London, London, United Kingdom

8 ²Centre for Epidemiological Modelling and Analysis, University of Nairobi, Kenya

9 ³Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, USA

10 ⁴Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford,
11 Oxford, United Kingdom

12 ⁵Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Old Road
13 Campus, Oxford, United Kingdom

14 ⁶ Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, UK

15

16 * Corresponding author

17 E-mail: john.ellis@imperial.ac.uk

18

19

20

21 **Abstract**

22 Schistosomiasis affects more than 230 million people worldwide. Control and elimination of this
23 parasitic infection is based on mass drug administration of praziquantel (PZQ), which has been in use
24 for several decades. Because of the limitations of the efficacy of PZQ especially against juvenile worms,
25 and the threat of the emergence of resistance, there is a need to consider alternative formulations or
26 delivery methods, or new drugs that could be more efficacious. We use an individual-based stochastic
27 model of parasite transmission to investigate the effects of possible improvements to drug efficacy.
28 We consider an increase in efficacy compared to PZQ, as well as additional efficacy against the juvenile
29 life stage of schistosome parasites in the human host, and a slow-release formulation that would
30 provide long-lasting efficacy for a period of time following treatment.

31 Analyses suggest a drug with a high efficacy of 99%, or with efficacy lasting 24 weeks after treatment,
32 are the two most effective individual improvements to the drug profile of PZQ. A drug with long lasting
33 efficacy is most beneficial when MDA coverage is low. However, when prevalence of infection has
34 already been reduced to a low level, a high efficacy is the most important factor to accelerate
35 interruption of transmission. Our results indicate that increased efficacy against juvenile worms can
36 only result in modest benefits, but the development of a new drug formulation with higher efficacy
37 against adult worms or long-lasting efficacy would create an improvement to the community impact
38 over the currently used formulation.

39 **Author summary**

40 The World Health Organization has set the target of elimination of schistosomiasis as a public health
41 problem by 2030. Currently, praziquantel is the sole drug used in mass drug administration (MDA) for
42 schistosomiasis, raising concerns about the potential evolution of resistance and whether an
43 improved drug profile would be necessary to achieve elimination and the more ambitious goal of
44 interruption of transmission. We present the results from an individual-based stochastic
45 mathematical model that simulates schistosome transmission and the impact of MDA. Three

46 potential improvements to the properties of the drug are considered: improved efficacy, long lasting
47 efficacy post a single treatment and improved efficacy against the juvenile life stage of the
48 schistosome. Our findings reveal that with good coverage, an improved drug efficacy is best at
49 reducing prevalence and achieving interruption of transmission. However, when MDA quality is
50 compromised due to low coverage, infrequent treatment or high rates of non-adherence, then a
51 long-lasting efficacy performs best. There is only a modest benefit of improved drug efficacy against
52 juvenile schistosomes. These results highlight the importance of good MDA program and inform
53 future drug development aims.

54

55 **Introduction**

56 The human schistosome parasites are parasitic flatworms that cause schistosomiasis, a disease that
57 affects more than 230 million people worldwide (1). There are three main species responsible for
58 human infection: *Schistosoma mansoni*, *Schistosoma haematobium* and *Schistosoma japonicum*. Each
59 species cover different geographic areas, *S. mansoni* is endemic in several countries in Africa and the
60 Caribbean, *S. haematobium* is endemic in Africa and Middle East, and *S. japonicum* is endemic in Asia
61 (2). Like several other neglected tropical diseases (NTDs), mass drug administration (MDA) is a key
62 component in the control and elimination programmes of schistosomiasis. Currently, praziquantel
63 (PZQ) is the only drug available for use against schistosomes and has been in use for over 40 years (3).
64 Because of the high disease burden, schistosomiasis has been targeted for elimination as a public
65 health problem by the World Health Organization in several countries by 2030 (4). However, attaining
66 this goal will likely require very high levels of coverage of MDA (5), as well as improvements in access
67 to safe water, sanitation and hygiene (WASH) and possibly some form of snail control (World Health
68 Organization, 2022). As there is the potential for *Schistosoma* species to develop resistance against
69 PZQ, which also has other limitations such as a low efficacy against the juvenile stage in the
70 schistosome life cycle, alternative drugs have been considered (8,9). An ideal drug would be efficacious

71 against all stages of the life cycle and include other benefits such as a slow-release mechanism that
72 could act to provide a longer duration of protection post treatment.

73 The schistosome life cycle is complex, going through multiple development stages (10,11). When a
74 free-living cercaria infects a human host by penetrating the skin, it goes on a journey through the body,
75 via the vascular system. Juvenile worms travel to the lungs and the liver, before reaching the intestine
76 (*S. mansoni* and *S. japonicum*) or bladder (*S. haematobium*) where they typically remain for 5-10 years
77 as adult worms (12).

78 Detailed examination of the life cycle within a human host is difficult but estimates of the length of
79 time between infection and egg production in mice hosts has been estimated to be 36-38 days (13). In
80 that time, the proportion of juvenile worms surviving to maturity has been found to be approximately
81 40% (10,14). Studies of the human immune response have found a similar time span of 4 to 6 weeks
82 between infection and detection of antibodies targeting adult worms (15).

83 PZQ has been found to be ineffective against juvenile worms, possibly due to their location within the
84 body at the time of treatment (8,16,17). For example, one study found that the concentration of PZQ
85 required to reduce the worm burden by 50% was 30 times higher when treating after 4 weeks,
86 compared to 7 weeks (14). Alternatives to PZQ have been suggested for their efficacy against juveniles
87 (8,18), however the impact that this would have at a population transmission level is unknown.

88 An alternative approach to targeting juveniles at the time of treatment, is to instead administer a slow-
89 release drug, which will continue to kill adult worms for several weeks post pill swallowing. Research
90 has shown that the slow-release delivery of drugs is effective against schistosomes (19,20). If such a
91 treatment were applied during MDA, it could theoretically target juvenile worms as they mature. If the
92 period of slow release is sufficiently long (longer than the typical maturation period of juveniles), or if
93 the new drug was efficacious against juveniles as well, there is also the added benefit of giving lasting
94 protection against new infections for a period after treatment.

95 Intuition suggests that coverage and efficacy are the two most important factors in an MDA program
96 and the product of the two will give a good reflection on its effectiveness. However, intuition is less
97 reliable when additional parameters are included, such as the length of time that efficacy will last after
98 treatment. In cases such as this, mathematical models are valuable tools for helping to formulating
99 policy and in drug design, by facilitating quantitative analyses of the impact of different improvements
100 at the population level in the drug profile of action on the parasite.

101 In this paper, we investigate the impact of drug profile improvements to the current practice of using
102 PZQ in MDA, employing an individual based stochastic mathematical model of the transmission and
103 mass drug treatment of *S. mansoni* and *S. haematobium*. We assess via simulations additional efficacy
104 against juvenile worms as well as adult worms, long lasting efficacy that gives protection against adult
105 worms for several weeks post treatment, and an improvement in drug efficacy against adult worms
106 only. To measure the effectiveness of each of these improvements, we show the average time taken
107 to reach interruption of transmission based on 200 repeated simulations, i.e. zero prevalence in the
108 entire population.

109 **Methods**

110 **Model formulation**

111 We use a stochastic individual based model developed at Imperial College London (the Imperial model)
112 that is based on the deterministic model that has been described in previous publications (21,22). To
113 include the juvenile stage in a human we adjust the model of mean adult worm burden as a function
114 of age and time, $M(a, t)$, to include the mean juvenile worm burden $J(a, t)$, so that in the deterministic
115 version,

$$116 \quad \frac{\partial J(a, t)}{\partial t} + \frac{\partial J(a, t)}{\partial a} = L\beta(a) - \mu J(a, t) - \sigma_J J(a, t),$$

$$117 \quad \frac{\partial M(a, t)}{\partial t} + \frac{\partial M(a, t)}{\partial a} = \mu J(a, t) - \sigma_M M(a, t),$$

118 where L represents the concentration of the infectious material in the environment, $\beta(a)$ is the age-
119 related contact rate, μ is the maturation rate of juvenile worms, and σ_J and σ_M are the natural death
120 rates of juvenile and adult worms respectively.

121 In the Imperial model, infection and maturation of juvenile worms and death of juvenile and adult
122 worms are discrete events, modelled as a Poisson process. All other details are as described in previous
123 publications (23–25); we assume the worms are monogamous and have a negative binomial
124 distribution which arises from a gamma distributed predisposition to infection amongst the individual
125 human hosts. Individuals also have an age-dependent contact rate with infectious material, and the
126 same age-dependence is also included in the output of eggs, which is density-dependent (26).

127 We also replicate some of the simulations with the SCHISTOX model, developed at the University of
128 Oxford (27,28).

129 **MDA treatment**

130 Starting in a closed, untreated population, we simulate biannual MDA, with a coverage of 75% in the
131 community (everyone over the age of 2). We assume that treatment is delivered at random at each
132 round. We first consider a ‘baseline’ approach, whereby MDA of PZQ occurs with an efficacy of 86.3%
133 against *S. mansoni*, or 94% against *S. haematobium* (29). The effect of the drug is assumed to be
134 immediate, so that any adult worm in a host that is treated will have a probability of dying at the time
135 of treatment.

136 When considering improvements to treatment that include efficacy against juvenile worms, they are
137 also killed at the time of treatment, with the same efficacy as for adult worms. In the slow-release
138 treatment, we assume that MDA still occurs as normal, but there is a fixed period of time following
139 treatment whereby a juvenile worm that reaches maturation will die with the same probability as the
140 original drug efficacy. We consider efficacious periods of 8, 16 and 24 weeks. When there is a slow-

141 release treatment that also has efficacy against juveniles, the worm will be killed at the time of
142 infection, rather than the time of maturation.

143 Initially we investigate the impact of improving drug efficacy to 99%, with different levels of coverage
144 and at different baseline prevalences (R_0 values) and record the length of time taken to reach
145 interruption of transmission (IOT) up to a maximum of 20 years after the start of the MDA programme.
146 We define this as the time taken for 90% of the 200 simulation runs to reach a 0% prevalence of
147 infection, using the Imperial and SCHISTOX models (22,27). Later, we consider the impacts of additional
148 improvements to the drug profile by adapting the Imperial model. Here we restrict our focus to a
149 scenario with high levels of transmission ($R_0 = 1.4-4$, $k=0.24$), with an initial baseline prevalence of
150 $>50\%$. For each improvement to drug efficacy, we show the mean prevalence and the mean time to
151 reach different prevalence thresholds, including IOT (0% prevalence). We also consider alterations to
152 the MDA whereby treatment occurs annually instead of biannually, or a small proportion of the
153 population (the 'never treated', set at a range of values between 1 to 5%) are permanently excluded
154 from MDA and never receive treatment. The parameter values used in model simulations are
155 documented in Table 1 for *S mansoni* and in Table 2 for *S haematobium*.

156 *Table 1: Parameter values for Schistosoma mansoni.*

| Parameter | Value | Reference |
|---------------------------------|-----------|------------|
| Fecundity (eggs/female/sample) | 0.34 | (30–32) |
| Aggregation parameter | 0.04-0.24 | (22,33) |
| Density dependent fecundity | 0.0007 | (22,34) |
| Adult worm life span (years) | 5.7 | (12,22,30) |
| Juvenile worm life span (weeks) | 5 | (13) |
| Juvenile survival rate | 0.4 | (10,14) |

| | | |
|---|---------------------|------------|
| Low adult burden setting: age specific contact rates for 0-5, 5-10, 10-16, 16+ years old | 0.01, 1.2, 1, 0.02 | (34,35) |
| High adult burden setting: age specific contact rates for 0-5, 5-12, 12-20, 20+ years old | 0.01, 0.61, 1, 0.12 | (34,35) |
| Drug efficacy | 86.3% | (29) |
| Aggregation of diagnostic | 0.87 | (31,32,36) |
| Basic reproduction number (Imperial model) | 1.2-4 | - |
| Contact rate (SCHISTOX model) | 0.34 – 2 | - |

157

158 *Table 2: Parameter values for Schistosoma haematobium.*

| Parameter | Value | Reference |
|---|--------------|-----------|
| Fecundity (eggs/female/10 ml sample) | 3.6 | (37,38) |
| Aggregation parameter | 0.04-0.24 | (33) |
| Density dependent fecundity | 0.0006 | (22) |
| Adult worm life span (years) | 4 | (21,39) |
| Juvenile worm life span (weeks) | 5 | (13) |
| Juvenile survival rate | 0.4 | (10,14) |
| Age specific contact rates for 0-5, 5-10, 10+ years old | 0.3, 1, 0.02 | (25) |
| Drug efficacy | 94% | (29) |
| Aggregation of diagnostic | 0.5 | (33) |
| Basic reproduction number (Imperial model) | 1.2-2 | - |
| Contact rate (SCHISTOX model) | 0.34 – 0.5 | |

159 Results

160 The effect of drug efficacy on the ability to achieve IOT within 20 years from different baseline
161 prevalences is shown in Table 3, along with the effect of MDA coverage levels and the proportion of
162 the population that is never treated. For both age profiles used to model *S. mansoni*, where IOT can
163 be reached within 20 years, an increased 99% efficacy can reduce the time taken by up to four years.
164 The benefits are smaller with *S. haematobium* but note that we assume the efficacy of PZQ is already
165 94% for this parasite so the increase in efficacy is smaller. Most importantly, in both cases, if the
166 coverage with PZQ is 60%, a bigger decrease in time to IOT can be attained with an increase in coverage
167 compared to an increase in efficacy. The largest impact on reaching IOT is the proportion of the
168 population that are systematically never treated. In scenarios with a high baseline prevalence (high R_0
169 value), it is impossible to reach IOT if any of the population are never treated. In moderate prevalences
170 it is possible in some scenarios when the never treated is 1% and in low prevalence settings (small R_0
171 values but >1) it is possible but can require up to 10 years of additional MDA. If the proportion never
172 treated is as high as 5% then it is not possible to achieve IOT for any scenario we considered.

173

174 *Table 3: Number of years of MDA required for interruption of transmission when varying the baseline prevalence, MDA*
175 *coverage, the proportion of the population systematically never treated and the drug efficacy. We model S. mansoni with a*

176 low and high adult burden and *S. haematobium*. MDA is annual when the baseline prevalence is low or moderate and
 177 biannual if the baseline prevalence is high.

| | | S. mansoni, low adult burden | | | | S. mansoni, high adult burden | | | | S. haematobium | | | |
|---------------------|--------------------------|------------------------------|--------------|------------------------|--------------|-------------------------------|--------------|------------------------|--------------|------------------------|--------------|------------------------|--------------|
| | | 60% community coverage | | 75% community coverage | | 60% community coverage | | 75% community coverage | | 60% community coverage | | 75% community coverage | |
| Baseline prevalence | Proportion never treated | 86.3% efficacy | 99% efficacy | 86.3% efficacy | 99% efficacy | 86.3% efficacy | 99% efficacy | 86.3% efficacy | 99% efficacy | 94% efficacy | 99% efficacy | 94% efficacy | 99% efficacy |
| Low (8%) | 0% | 14 | 11-12 | 10 | 8 | 14-16 | 12 | 10-11 | 8-9 | 12 | 11 | 9-10 | 8-9 |
| | 1% | 18-19 | 18-19 | 17 | 16 | 20->20 | 18->20 | 18-20 | 19 | 16 | 14 | 13 | 13 |
| | 5% | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 |
| Moderate (13%-49%) | 0% | 15-19 | 13-15 | 10-14 | 9-10 | 16-20 | 13-17 | 12-16 | 9-11 | 14-16 | 13-14 | 10-12 | 9-11 |
| | 1% | >20 | >20 | >20 | 19->20 | >20 | >20 | >20 | >20 | 18->20 | 17->20 | 19->20 | 15->20 |
| | 5% | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 |
| High (51%-70%) | 0% | 8-15 | 7-12 | 6-10 | 5-8 | 9-15 | 7-13 | 7-11 | 5-9 | 8-11 | 8-10 | 6-9 | 6-8 |
| | 1% | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 |
| | 5% | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 | >20 |

178

179 To examine the effects of additional improvements to a potential new drug formulation, we now
 180 restrict our attention to an area of high baseline prevalence (high values of the basic reproductive
 181 number $R_0 - R_0 = 3.3-4$ for *S mansoni*, $R_0 = 2$ for *S haematobium*). As shown in Table 4, in this scenario
 182 the entire community must be available for treatment (0% never treated) to achieve IOT, no matter
 183 the improvements to the drug profileTable 4. If this is the case, a new drug with an efficacy against

184 juvenile and adult worms, lasting 24 weeks can reach a 0% prevalence of *S. mansoni* faster than the
 185 current drug efficacy profile by up to four years, depending on the age intensity profile, equivalent to
 186 six rounds of MDA. The same drug would only be two years faster when used against *S. haematobium*,
 187 probably due to the already high efficacy of PZQ against this species. This drug with the combination
 188 of efficacy against juvenile worms and a slow-release period is the fastest approach to achieve IOT in
 189 this scenario but is only marginally better than a slow-release drug without efficacy against juveniles,
 190 or one that has a near-perfect 99% efficacy against adult worms. Little benefit is seen from a drug that
 191 has efficacy against juvenile worms without any additional improvements in the drug properties
 192 profile.

193 *Table 4: Number of years of MDA required for interruption of transmission, starting at a high baseline prevalence (>50%). The*
 194 *baseline efficacy is 86.3% for S. mansoni and 94% for S. haematobium.*


| Species and infection intensity age profile | Proportion never treated | Efficacy against adults only | | Additional efficacy against juveniles: 86.3% or 94% | Slow-release period (weeks) | | | 24 week slow-release period and additional efficacy against juveniles |
|---|--------------------------|------------------------------|-----|---|-----------------------------|-----|-----|---|
| | | 86.3% or 94% | 99% | | 8 | 16 | 24 | |
| S. mansoni, low adult burden | 0% | 8-11 | 6-8 | 8-10 | 7-9 | 7-9 | 7-8 | 7-8 |
| | 1% | >20 | >20 | >20 | >20 | >20 | >20 | >20 |
| S. mansoni, high adult burden | 0% | 8-12 | 6-9 | 8-11 | 7-10 | 7-9 | 7-9 | 7-8 |
| | 1% | >20 | >20 | >20 | >20 | >20 | >20 | >20 |
| S. haematobium | 0% | 8-9 | 7-8 | 7-9 | 7-8 | 7-8 | 7-8 | 6-8 |
| | 1% | >20 | >20 | >20 | >20 | >20 | >20 | >20 |

195

196 These results are broken down further for the *S. mansoni*, low adult burden case in Figure 1, showing
 197 the reduction of prevalence, the probability of achieving elimination over time and the time to reach

198 different prevalence thresholds. This shows how the best performing drug, with 99% efficacy against
199 adult worms, quickly reduces the prevalence in just over 6 years on average, compared with the
200 baseline case (86.3% efficacy against adult worms), which takes just under 8 years in total. Note that
201 results from the bar chart differ from those in Table 4, as the former was calculated using the mean,
202 whereas the latter shows the time for 90% of simulations to reach elimination.


203 Interestingly, most improvements to the speed of the reduction of prevalence are realised early during
204 MDA, when the prevalence is still high. For example, a drug with a 24-week efficacy against adult and
205 juvenile worms reduces the prevalence from 70% to 50% in 0.8 years and 50% to 25% in 1 year,
206 compared to the baseline case which takes 1.1 and 1.7 years to reach those intervals respectively.
207 However, the time taken to reduce the prevalence from 10% to 1% and from 1% to 0%, takes 1.6 and
208 1.2 years with a 24-week efficacy period, compared to 1.8 and 1.1 years for the baseline case. The only
209 improvement that outperforms the baseline case consistently throughout MDA is a drug with the high
210 99% efficacy. A 99% efficacy drug outperforms all other drug characteristics at high (>50%) and low
211 (<10%) prevalences, but it is not as effective as a drug with efficacy lasting at least 16 weeks at the
212 moderate prevalences (10%-50%).



213

214 *Figure 1: Results of biannual MDA with 75% community coverage against S. mansoni with a low adult burden, starting with*
 215 *a high baseline prevalence. (A) Prevalence, based on worm counts during MDA with a range of drug improvements over time.*
 216 *(B) The probability of reaching interruption of transmission with each drug improvement over time. (C) Years of MDA required*
 217 *to reach interruption of transmission (bar height) and the time taken to reach different prevalence thresholds (coloured*
 218 *blocks).*


219 If MDA is administered annually rather than biannually, as shown in Figure 2, drugs with long lasting
 220 efficacy (slow release) perform better than any other. If efficacy were to last for 24 weeks, the time
 221 taken to reach elimination would be 7 years quicker than the baseline case. In this scenario, a drug
 222 with 99% efficacy performs similarly to one which has 86% efficacy against juvenile worms, which
 223 achieve elimination approximately two years quicker than the baseline case. However, once a 10%
 224 prevalence threshold is reached, a drug with 99% efficacy is the better option, taking 4 years to achieve
 225 elimination compared to approximately 5 years in all other cases.



226


227 *Figure 2: As in Figure 1, except MDA is administered annually instead of biannually. (A) Prevalence, based on worm counts*
 228 *during MDA with a range of drug improvements over time. (B) The probability of reaching interruption of transmission with*
 229 *each drug improvement over time. (C) Years of MDA required to reach interruption of transmission (bar height) and the time*
 230 *taken to reach different prevalence thresholds (coloured blocks).*

231 A similar effect is seen when the frequency is restored to biannual MDA, but community coverage is
 232 reduced to 40%, as shown in Figure 3. The time to achieve IOT is approximately 25 years but can be
 233 reduced to approximately 16 years with a drug that has efficacy lasting 24 weeks. In both cases where
 234 fewer treatments are administered, the reduction in time to reach each prevalence threshold and
 235 achieve IOT from an improved drug characteristic is greater than when coverage and frequency is high.
 236 This is also the case when the efficacy of PZQ is lower than the 86.3% we have otherwise assumed, as
 237 shown in Figure 4 where the baseline efficacy is 60%. If this were the case then the benefit of a new
 238 drug with 99% efficacy is obvious, but a slow-release formulation lasting 24 weeks would decrease the
 239 time to achieve IOT, even with the same 60% efficacy.



240


241 *Figure 3: As in Figure 1, except MDA coverage is 40% of the community. (A) Prevalence, based on worm counts during MDA*
 242 *with a range of drug improvements over time. (B) The probability of reaching interruption of transmission with each drug*
 243 *improvement over time. (C) Years of MDA required to reach interruption of transmission (bar height) and the time taken to*
 244 *reach different prevalence thresholds (coloured blocks).*



245

246 *Figure 4: As in Figure 1, except the efficacy of PZQ is assumed to be 60%. (A) Prevalence, based on worm counts during MDA*
 247 *with a range of drug improvements over time. (B) The probability of reaching interruption of transmission with each drug*
 248 *improvement over time. (C) Years of MDA required to reach interruption of transmission (bar height) and the time taken to*
 249 *reach different prevalence thresholds (coloured blocks).*

250 Figure 5 illustrates the importance of good adherence amongst the population eligible for treatment.
 251 Here, MDA is administered biannually again but 1% of the population is systemically excluded from
 252 treatment. As in Table 4, this shows that IOT is difficult to achieve when this is the case. While some
 253 drug improvements decrease the time needed to reduce prevalence to 10%, the time taken to reach
 254 elimination from a 10% or 1% prevalence is much larger than when everyone adheres to treatment
 255 during the course of MDA. Once the 10% prevalence threshold is passed, there are no benefits from
 256 improvements to treatment and the lines in Figure 5A and B converge, while the variation in bar
 257 heights in Figure 5C is very limited.



258

259 *Figure 5: As in Figure 1, except 1% of the population are systematically excluded from MDA and are therefore never treated.*

260 *(A) Prevalence, based on worm counts during MDA with a range of drug improvements over time. (B) The probability of*

261 *reaching interruption of transmission with each drug improvement over time. (C) Years of MDA required to reach interruption*

262 *of transmission (bar height) and the time taken to reach different prevalence thresholds (coloured blocks).*

263 Although the above results show the potential benefits of improved drug characteristics, it is clear

264 from comparing the baseline in Figure 1 with Figures 2-5 that delivering frequent MDA with good

265 coverage with no proportion never treated is more important than the characteristics of the drug. To

266 illustrate this, we compare the effect of PZQ with good coverage and assuming an efficacy of 86.3%,

267 against an ideal new drug that has a 99% efficacy against adults and juveniles and a 24-week slow

268 release period, with suboptimal MDA. The results in Figure 6 show that while the ideal drug is very

269 effective at bringing down prevalence and achieving IOT within 5 years (panels A and E), when the

270 frequency of MDA is reduced to annual administration the results are very similar to the effects of PZQ

271 with biannual MDA (panels B and F). When coverage is reduced to 40% (panels C and G), the ideal drug

272 will initially reduce prevalence faster than PZQ with ideal MDA but is much slower to achieve IOT. This
273 is also the case when 5% of the population are systematically never treated (panels D and H), where
274 the prevalence falls much quicker with the ideal drug, but IOT is impossible to achieve within 15 years
275 and prevalence is lower when using PZQ with ideal treatment after approximately 5 years.




Figure 6: A comparison between PZQ with ideal MDA, defined as 75% community coverage, biannual, 0% NT (red lines), and an ideal improved drug with 99% efficacy against juvenile and adult worms, lasting for 24 weeks. Individual plots show prevalence (A-D) and probability of interruption of transmission (E-H) for 15 years after starting MDA. (A, E) Comparison between PZQ (red) and an ideal drug (blue), both with ideal coverage. (B, F) The ideal drug is given annually instead of biannually (cyan). (C, G) Coverage of the ideal drug is reduced to 40% (yellow). (D, H) 5% of the population are permanently excluded from MDA with the ideal drug (magenta).

276

277 Discussion

278 Use of PZQ has long been the principal approach to reducing the prevalence of schistosome parasite
279 infection and controlling morbidity due to high burdens of worms. However, the ambition to achieve
280 the elimination of transmission in defined settings has led to research into new drugs, alongside other
281 interventions such as improvements in water, sanitation and hygiene, plus snail control (the
282 intermediate host in the life cycle) (8). Many of these ideas have yet to be tested at a population level.
283 Past discussion about what might be a sensible set of properties for any new drug to support
284 schistosomiasis control have been based largely on what technically might be possible (e.g. activity
285 against juvenile worms and slow-release technologies). The research described in this paper sets out

286 to provide a more quantitative background for such discussions by investigating via simulation what
287 the population level impact of different drug properties would be based on the predictions of a
288 mathematical model of the transmission of *S. mansoni* and *S. haematobium* and MDA impact. The
289 magnitude of the improvements we consider are not based on products currently in development.
290 However, the results provide guidance on the effect that each improvement will have at the
291 community level.

292 Although a lack of efficacy against juvenile worms is often highlighted as a problem with PZQ, we find
293 that at a population level this has little impact on reducing prevalence. This is due to the time it takes
294 to mature in the human host being small relative to adult worm life expectancy. We have assumed that
295 the juvenile maturation period is 5 weeks on average compared to the adult life span of 5.7 years for
296 *S. mansoni* and 4 years for *S. haematobium*. This means that the number of juveniles as a proportion
297 of the total number of worms in the population is small, approximately 1.5-2.5%. Therefore, even the
298 impact of a drug with 100% efficacy against juvenile worms would only have the effect of improving
299 efficacy against all worms by 2.5% at best.

300 It is therefore unsurprising that a drug with high efficacy against adult worms achieves better outcomes
301 than one with an efficacy against juveniles but no improvement in efficacy against adults. A drug with
302 99% efficacy against adult worms is effective at decreasing the time to achieve IOT, particularly when
303 coverage is also good. Similarly, it is unsurprising that most of the improvements don't show
304 substantially better results for *S. haematobium* compared to the baseline (see Table 4: Number of years
305 of MDA required for interruption of transmission, starting at a high baseline prevalence (>50%). The
306 baseline efficacy is 86.3% for *S. mansoni* and 94% for *S. haematobium*. , because the efficacy is already
307 quite high against this schistosome species. The estimate for the efficacy of PZQ used in this model is
308 one that is commonly referred to (23,24), however most estimates of egg reduction rate range from
309 60-100% (40). If resistance is being developed, the efficacy of PZQ in the field could be much lower. If
310 this is the case, or if efficacy is less than assumed here, the benefits of a new drug with higher efficacy

311 are obviously highly desirable, but a slow-release period would also be beneficial, even if efficacy
312 remained low. The caveat to this is that a slow-release formulation may affect the way resistance
313 develops.

314 What is surprising, perhaps, is the result that when a low prevalence is already reached, there appears
315 to be no benefit to drug improvements, with the exception of a drug with a very high efficacy. This is
316 counter-intuitive, as one might expect that there would be value in killing juveniles when approaching
317 elimination. However, at lower prevalences, the rate of new infections will have already slowed, and
318 thus the number of juveniles will be small, whereas there will still be many adult worms in the
319 population particularly if not everyone eligible has received treatment, or the efficacy against adults is
320 not sufficiently high. A drug with high efficacy against adult worms only is also the most effective at
321 reducing prevalence from a high baseline level as almost everyone who is treated will be free from
322 infection. However, at moderate prevalences, drugs with a long-lasting efficacy are most effective as
323 they provide protection from reinfection and reduce the immediate bounce back in prevalence after
324 MDA.

325 In this paper we mostly focus on the goal of interruption or elimination of transmission and for the
326 purpose of the model, define this as a complete absence of worms in the population. Although this
327 can be achieved in a closed community, there is always the potential for infection to be reintroduced
328 and prevalence to bounce back if infected people move into or visit areas that have cleared infection
329 by high coverage of MDA over many years (41). In this scenario where prevalence is low, high efficacy
330 against adult worms and good coverage of MDA, with no proportion never treated, are more important
331 than the other potential improvements.

332 The improvements in the properties of an anti-schistosome infection drug were chosen to illustrate
333 how they might impact infection at a community level. The main conclusion arising from the simulation
334 studies is that high coverage and high efficacy are key to success, but long-lasting efficacy can also be
335 very effective. This is particularly the case at moderate and high prevalences, and when MDA coverage

336 is not ideal. Activity against juvenile worms is of limited additional benefit. When coverage is low, or
337 some of the population are systematically excluded from MDA, even an ideal drug with very high
338 efficacy that lasts for 24 weeks is not as effective as PZQ with good coverage. For many helminth
339 infections WHO has recommended MDA coverage targets of around 75% for school aged children. We
340 believe this is too low. Coverage targets should be around 80-90% of the total population in moderate
341 or high transmission settings if transmission interruption is the goal. As has already been shown
342 elsewhere, good coverage over the course of MDA year by year, with a very low proportion of never
343 treated, is vital (5,28). WASH interventions are also strongly recommended as a key supplement to
344 MDA and for long lasting general improvements in health (7).

345 **References**

- 346 1. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. *The Lancet*.
347 2014;383(9936):2253–64.
348
- 349 2. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its
350 control. *Acta Trop*. 2000 Oct 23;77(1):41–51.
351
- 352 3. Villamizar-Monsalve MA, López-Abán J, Vicente B, Peláez R, Muro A. Current drug strategies
353 for the treatment and control of schistosomiasis. *Expert Opin Pharmacother*. 2024 Mar 27;1–
354 12.
355
- 356 4. World Health Organization. Ending the neglect to attain the sustainable development goals: a
357 road map for neglected tropical diseases 2021–2030. 2021.
358

- 359 5. Anderson RM, Turner HC, Farrell SH, Yang J, Truscott JE. What is required in terms of mass
360 drug administration to interrupt the transmission of schistosome parasites in regions of
361 endemic infection? *Parasit Vectors*. 2015; 8(1):1–11.
362
- 363 6. Mekete K, Ower A, Dunn J, Sime H, Tadesse G, Abate E, et al. The Geshiyaro Project: A study
364 protocol for developing a scalable model of interventions for moving towards the interruption
365 of the transmission of soil-transmitted helminths and schistosome infections in the Wolaita
366 zone of Ethiopia. *Parasit Vectors*. 2019; 12(1):1–12.
367
- 368 7. World Health Organization. WHO Guideline on control and elimination of human
369 schistosomiasis. 2022. 142 p.
370
- 371 8. Caldwell N, Afshar R, Baragaña B, Bustinduy AL, Caffrey CR, Collins JJ, et al. Perspective on
372 Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop
373 at Wellcome Collection, London, September 2022. *ACS Infect Dis*. 2023; 9(5):1046–55.
374
- 375 9. Doenhoff MJ, Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for
376 control in areas with endemic disease and prospects for drug resistance. *Expert Rev Anti
377 Infect Ther*. 2006; 4(2):199–210.
378
- 379 10. Wilson RA. The saga of schistosome migration and attrition. 2009;(January):1581–92.
380
- 381 11. Jones MK, Lustigman S, Loukas A. Tracking the Odysseys of Juvenile Schistosomes to
382 Understand Host Interactions. *PLoS Negl Trop Dis*. 2008; 2(7):e257.
383

- 384 12. Fulford AJC, Butterworth AE, Ouma JH, Sturrock RF. A statistical approach to schistosome
385 population dynamics and estimation of the life-span of *Schistosoma mansoni* in man.
386 *Parasitology*. 1995; 110(3):307–16.
387
- 388 13. Fallon PG, Mubarak JS, Fookes RE, Niang M, Butterworth AE, Sturrock RF, et al. *Schistosoma*
389 *mansoni*: Maturation rate and drug susceptibility of different geographic isolates. *Exp*
390 *Parasitol*. 1997; 86(1):29–36.
391
- 392 14. Pica-mattocchia L, Cioli D. Sex- and stage-related sensitivity of *Schistosoma mansoni* to in vivo
393 and in vitro praziquantel treatment. 2004; 34:527–33.
394
- 395 15. Langenberg MCC, Hoogerwerf MA, Koopman JPR, Janse JJ, Kos-van Oosterhoud J, Feijt C, et al.
396 A controlled human *Schistosoma mansoni* infection model to advance novel drugs, vaccines
397 and diagnostics. *Nature Medicine* 2020 26:3. 2020; 26(3):326–32.
398
- 399 16. Stothard JR, Sousa-Figueiredo JC, Betson M, Bustinduy A, Reinhard-Rupp J. Schistosomiasis in
400 African infants and preschool children: let them now be treated! *Trends Parasitol*. 2013;
401 29(4):197.
402
- 403 17. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. *Schistosoma mansoni*: Chemotherapy of
404 infections of different ages. *Exp Parasitol*. 1986; 61(3):294–303.
405
- 406 18. Buchter V, Schneeberger PHH, Keiser J. Validation of a human-serum-based in vitro growth
407 method for drug screening on juvenile development stages of *Schistosoma mansoni*. *PLoS*
408 *Negl Trop Dis*. 2021; 15(3):e0009313.
409

- 410 19. Schver GCRM, Sun DD, Costa SPM, Silva KER, Oliveira JF, Rolim LA, et al. Solid dispersions to
411 enhance the delivery of a potential drug candidate LPSF/FZ4 for the treatment of
412 schistosomiasis. *European Journal of Pharmaceutical Sciences*. 2018; 115:270–85.
413
- 414 20. Gold D, Alian M, Domb A, Karawani Y, Jbarien M, Chollet J, et al. Elimination of *Schistosoma*
415 *mansoni* in infected mice by slow release of artemisone. *Int J Parasitol Drugs Drug Resist*.
416 2017 ;7(2):241–7.
417
- 418 21. Anderson RM, May RM. Helminth Infections of Humans: Mathematical Models, Population
419 Dynamics and Control. *Adv Parasitol*. 1985; 24.
420
- 421 22. Anderson RM, Turner HC, Farrell SH, Truscott JE. Studies of the Transmission Dynamics,
422 Mathematical Model Development and the Control of Schistosome Parasites by Mass Drug
423 Administration in Human Communities. Vol. 94, *Advances in Parasitology*. Elsevier Ltd; 2016.
424 199–246 p.
425
- 426 23. Kura K, Ayabina D, Hollingsworth TD, Anderson RM. Determining the optimal strategies to
427 achieve elimination of transmission for *Schistosoma mansoni*. *Parasit Vectors*. 2022; 15(1):1–
428 9.
429
- 430 24. Kura K, Hardwick RJ, Truscott JE, Anderson RM. What is the impact of acquired immunity on
431 the transmission of schistosomiasis and the efficacy of current and planned mass drug
432 administration programmes? *PLoS Negl Trop Dis*. 2021; 15(12):1–17.
433

- 434 25. Kura K, Hardwick RJ, Truscott JE, Toor J, Hollingsworth TD, Anderson RM. The impact of mass
435 drug administration on *Schistosoma haematobium* infection: what is required to achieve
436 morbidity control and elimination? *Parasit Vectors*. 2020; 13(1):1–10.
437
- 438 26. Medley G, Anderson RM. Density-dependent fecundity in *Schistosoma mansoni* infections in
439 man. *Trans R Soc Trop Med Hyg*. 1985;79(4):532–4.
440
- 441 27. Graham M, Ayabina D, Lucas TC, Collyer BS, Medley GF, Hollingsworth TD, et al. SCHISTOX: An
442 individual based model for the epidemiology and control of schistosomiasis. *Infect Dis Model*.
443 2021; 6:438–47.
444
- 445 28. Kura K, Mutono N, Basáñez MG, Collyer BS, Coffeng LE, Thumbi SM, et al. How Does
446 Treatment Coverage and Proportion Never Treated Influence the Success of *Schistosoma*
447 *mansoni* Elimination as a Public Health Problem by 2030? *Clinical Infectious Diseases*. 2024;
448 78(Supplement_2):S126–30.
449
- 450 29. Zwang J, Olliaro PL. Clinical Efficacy and Tolerability of Praziquantel for Intestinal and Urinary
451 Schistosomiasis—A Meta-analysis of Comparative and Non-comparative Clinical Trials. *PLoS*
452 *Negl Trop Dis*. 2014; 8(11):e3286.
453
- 454 30. Anderson RM, May RM. Population dynamics of human helminth infections: Control by
455 chemotherapy. *Nature*. 1982; 297(5867):557–63.
456
- 457 31. de Vlas S, Nagelkerke N, Habbema J. Statistical models for estimating prevalence and
458 incidence of parasitic diseases. Vol. 2, *Statistical Methods in Medical Research*. *Stat Methods*
459 *Med Res*; 1993; p. 3–21.

460

461 32. De Vlas SJ, Van Oortmarsen GJ, Habbema JDF, Gryseels B, Polderman AM, Vanoortmarsen
462 GJ, et al. A model for variations in single and repeated egg counts in *Schistosoma mansoni*
463 infections. *Parasitology*. 1992; 104(3):451–60.

464

465 33. Truscott JE, Gurarie D, Alsallaq R, Toor J, Yoon N, Farrell SH, et al. A comparison of two
466 mathematical models of the impact of mass drug administration on the transmission and
467 control of schistosomiasis. *Epidemics*. 2017; 18:29–37.

468

469 34. Turner HC, Truscott JE, Bettis AA, Farrell SH, Deol AK, Whitton JM, et al. Evaluating the
470 variation in the projected benefit of community-wide mass treatment for schistosomiasis:
471 Implications for future economic evaluations. *Parasit Vectors*. 2017; 10(1):1–15.

472

473 35. Toor J, Turner HC, Truscott JE, Werkman M, Phillips AE, Alsallaq R, et al. The design of
474 schistosomiasis monitoring and evaluation programmes: The importance of collecting adult
475 data to inform treatment strategies for *Schistosoma mansoni*. *PLoS Negl Trop Dis*. 2018;
476 12(10):1–15.

477

478 36. Toor J, Truscott JE, Werkman M, Turner HC, Phillips AE, King CH, et al. Determining post-
479 treatment surveillance criteria for predicting the elimination of *Schistosoma mansoni*
480 transmission. *Parasit Vectors*. 2019; 12(1):1–7.

481

482 37. Cheever AW. A quantitative post-mortem study of *Schistosomiasis mansoni* in man. *American*
483 *Journal of Tropical Medicine and Hygiene*. 1968; 17(1):38–64.

484

- 485 38. French MD, Churcher TS, Webster JP, Fleming FM, Fenwick A, Kabatereine NB, et al.
486 Estimation of changes in the force of infection for intestinal and urogenital schistosomiasis in
487 countries with schistosomiasis control initiative-assisted programmes. *Parasit Vectors*.
488 2015;8(1):558.
- 489
- 490 39. Anderson RM, May RM. *Infectious diseases of humans: dynamics and control*. Vol. 1, Trends in
491 Microbiology. Oxford university press; 1991. 202–203 p.
- 492
- 493 40. Fukushige M, Chase-Topping M, Woolhouse MEJ, Mutapi F. Efficacy of praziquantel has been
494 maintained over four decades (from 1977 to 2018): A systematic review and meta-analysis of
495 factors influence its efficacy. *PLoS Negl Trop Dis*. 2021; 15(3).
- 496
- 497 41. Collyer BS, Truscott JE, Mwandawiro CS, Njenga SM, Anderson RM. How important is the
498 spatial movement of people in attempts to eliminate the transmission of human helminth
499 infections by mass drug administration? *Philosophical Transactions of the Royal Society B:*
500 *Biological Sciences*. 2023; 378(1887).
- 501